Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1999 1
2000 1
2002 2
2003 2
2004 1
2005 3
2006 5
2007 4
2008 2
2009 10
2010 7
2011 5
2012 4
2013 4
2014 6
2015 6
2017 3
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 20052780

61 results

Results by year

Filters applied: . Clear all
Page 1
Phase I trial of sargramostim in pediatric Crohn's disease.
Kelsen JR, Rosh J, Heyman M, Winter HS, Ferry G, Cohen S, Mamula P, Baldassano RN. Kelsen JR, et al. Inflamm Bowel Dis. 2010 Jul;16(7):1203-8. doi: 10.1002/ibd.21204. Inflamm Bowel Dis. 2010. PMID: 20052780 Clinical Trial.
Sargramostim for active Crohn's disease.
Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ; Sargramostim in Crohn's Disease Study Group. Korzenik JR, et al. N Engl J Med. 2005 May 26;352(21):2193-201. doi: 10.1056/NEJMoa041109. N Engl J Med. 2005. PMID: 15917384 Free article. Clinical Trial.
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R; REACH Study Group. Hyams J, et al. Gastroenterology. 2007 Mar;132(3):863-73; quiz 1165-6. doi: 10.1053/j.gastro.2006.12.003. Epub 2006 Dec 3. Gastroenterology. 2007. PMID: 17324398 Clinical Trial.
Comparison of outcomes parameters for induction of remission in new onset pediatric Crohn's disease: evaluation of the porto IBD group "growth relapse and outcomes with therapy" (GROWTH CD) study.
Levine A, Turner D, Pfeffer Gik T, Amil Dias J, Veres G, Shaoul R, Staiano A, Escher J, Kolho KL, Paerregaard A, Martin de Carpi J, Veereman Wauters G, Koletzko S, Shevah O, Finnby L, Sladek M. Levine A, et al. Inflamm Bowel Dis. 2014 Feb;20(2):278-85. doi: 10.1097/01.MIB.0000437735.11953.68. Inflamm Bowel Dis. 2014. PMID: 24390062
Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children.
Hyams JS, Griffiths A, Markowitz J, Baldassano RN, Faubion WA Jr, Colletti RB, Dubinsky M, Kierkus J, Rosh J, Wang Y, Huang B, Bittle B, Marshall M, Lazar A. Hyams JS, et al. Gastroenterology. 2012 Aug;143(2):365-74.e2. doi: 10.1053/j.gastro.2012.04.046. Epub 2012 May 2. Gastroenterology. 2012. PMID: 22562021 Clinical Trial.
61 results